- The renoprotective effects of canagliflozin demonstrated in the CREDENCE study cannot yet be considered as an effect of the whole class of SGLT2 inhibitors2020 | Second Faculty of Medicine
- Canagliflozin reduces the risk of CKD progression in type 2 diabetes with nephropathy - main results of the CREDENCE study2019 | First Faculty of Medicine